Revenue

The S&P/TSX Composite's latest rebalance is more than a market footnote. It's a story of rising commodity players and struggling consumer-facing firms.

Lagunitas and Iron Maiden are hiring a 'Beer Roadie.' It's not just a dream job; it's a masterclass in experiential marketing and the future of brand loyalty.

Beyond the pitch, a massive government investment aims to leverage the FIFA World Cup to overhaul Canada's sport system and unite a nation.

With its new SYNMUE™ probiotic, SynbioTech is targeting the biological clock of our immune system. A deep dive into the science, the strategy, and the execution.

Allen Control Systems' massive funding for its autonomous Bullfrog weapon reveals a new reality: venture capital is now funding the future of warfare.

Cognizant claims an 'iPhone moment' for robotics with its new sovereign AI platform. But can it solve the deep architectural challenges of scaling AI in the real world?

The new Barbie stamp series is more than a tribute; it’s a calculated business strategy by the USPS to leverage a cultural icon for its own survival.

A new report reveals a stark disconnect: formal AI investments show no return, while a vast, ungoverned 'shadow AI' economy driven by employees delivers real gains.

AM Best affirms Victoria Insurance's 'Good' rating despite a shrinking footprint, revealing a high-stakes balancing act between a fortress balance sheet and immense market risks.

Legendary Fruit Co.'s massive acquisition of Gebbers Farms creates a new apple titan, but the court-supervised deal reveals a story of financial distress.

A $50,000 federal grant to plan a trail network in Niisaachewan Anishinaabe Nation is more than infrastructure—it's a step towards safety and cultural revival.

The brokerage's consistent top rankings aren't just about sales. A closer look reveals a powerful strategy blending legacy prestige with modern corporate muscle.

Most product launches fail not because of a bad product, but a flawed strategy. A new blueprint from Info-Tech Research Group reveals why and offers a fix.

With the approval of its advanced cancer drug Eratrectinib, Vcare PharmaTech challenges global rivals, showcasing China's AI-driven R&D and strategic ambition.

New research reveals AI is no longer just assisting IT—it's taking control. A deep dive into the shift to autonomous operations and what it means for leaders.

With a fresh $34.5M in capital, Volatus is set to expand manufacturing and advance its defense-grade drone tech. What does this signal for the industry?

A new pact with Galaxy Digital lets Morgan Stanley's elite clients swap crypto for ETPs. Is this the moment Wall Street fully embraces DeFi, or a risky new frontier?

Aiper's new partnership with charity: water isn't just philanthropy. It's a calculated move to link its backyard tech to the global water crisis, turning eco-conscious consumers into brand evangelists.

Market research shows doctors are eager to prescribe Moleculin's new AML drug, Annamycin. It offers hope where there is none, but can the company survive to deliver it?

As Florida celebrates National Homeownership Month, the dream of owning a home clashes with a perfect storm of insurance crises and affordability challenges.